Huppert, Laura A.
Green, Michael D.
Kim, Luke
Chow, Christine
Leyfman, Yan
Daud, Adil I.
Lee, James C. http://orcid.org/0000-0002-1762-1677
Funding for this research was provided by:
Parker Institute for Cancer Immunotherapy
Article History
Received: 1 May 2021
Accepted: 28 June 2021
First Online: 20 August 2021
Change Date: 24 September 2019
Change Type: Update
Change Details: The title contained a typo that was updated.
Competing interests
: A.D.: Consultant, BMS, Merck, Pfizer, Novartis, Incyte, Checkmate, Eisai. Research Funding: OncoSec, Pfizer, Merck, Novartis, GSK, BioNTech, Replimune, Exicure. Stock: TRex Bio, NEUVOGEN. The remaining authors declare no competing interests.